Date: September 19, 2023
Time: 11:00 AM (PST), 2:00 PM (EST), 8:00 PM (CET)
Current clinical methods used to identify epithelial ovarian cancer are often too late – when the cancer is at an advanced stage, leaving the patient with limited therapeutic options. Diagnosis is often hindered by a lack of routine screening, nonspecific symptoms, and the low specificity of imaging methods, all of which can have a heavy impact on prognosis while increasing the burden on patients and health system resources.
Clinically, protein biomarkers for ovarian cancer such as CA 125 and HE4 are routinely used by HCPs to provide insights on tracking treatment response and supporting the monitoring of disease progression or recurrence. Less appreciated is the ability of algorithms such as The Risk of Ovarian Malignancy Algorithm (ROMA) to help risk stratify patients presenting with an adnexal mass, thus providing clinicians with clearer patient management options.
This presentation will highlight three different clinical viewpoints (from a large academic medical center to a rural clinic) on how diagnostic tools can help improve diagnosis and management of epithelial ovarian cancer and potentially impact the patient journey.
- Understand how biomarkers play a role in aiding clinicians in triaging adnexal masses to determine whether surgery is needed and the right surgical setting
- Gain a perspective from three key opinion leaders on what the impact of a delayed diagnosis of ovarian cancer can mean for the patient, clinician, and the healthcare system
- Review the patient case studies to better understand the difference biomarkers can make along the patient journey
Webinars will be available for unlimited on-demand viewing after live event.
Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.